Curis

CRISPhase 3

Curis is a clinical-stage oncology company dedicated to developing novel therapies that slow or prevent cancer progression. Its lead asset, Emavusertib, is an oral IRAK4 inhibitor in clinical trials for IRAK4-driven leukemias and lymphomas. The company also benefits from a collaboration with Roche/Genentech on the commercialized drug Erivedge for advanced basal cell carcinoma, providing non-dilutive funding. Curis is strategically focused on hematologic malignancies and immune checkpoint modulation.

Market Cap

$10.6M

Focus

Small Molecules

AI Company Overview

Technology Platform

Focus on small molecule inhibitors targeting key oncology pathways including IRAK4, dual HDAC/PI3K, and immune checkpoints (TIM-3, PD-L1, VISTA).

Pipeline Snapshot

19 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
chondrocyte-alginate gel suspension	Vesicoureteral Reflux	Phase 3
CA-4948	Myelodysplastic Syndromes	Phase 2
Emavusertib + Zanubrutinib	Chronic Lymphocytic Leukemia	Phase 2
CUDC-907	Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations	Phase 2
Emavusertib + Ibrutinib	Relapsed Hematologic Malignancy	Phase 1/2

Funding History

Total raised: $97M

Debt$30MHealthCare Royalty PartnersJun 15, 2022

PIPE$25MBVF PartnersFeb 15, 2021

IPO$42MUndisclosedNov 15, 2000

Opportunities

Significant opportunity in targeting IRAK4-driven hematologic malignancies, a novel mechanism in a high-unmet-need population.

The oral immune checkpoint inhibitor platform, if successfully developed, could capture share in the large immuno-oncology market with a differentiated delivery mode.

Royalties from Erivedge provide a steady, non-dilutive income stream.

Risk Factors

High dependency on the clinical success of a single lead asset, Emavusertib.

Requires continual access to capital markets to fund operations amid persistent losses.

Faces intense competition in both the hematologic malignancy and immuno-oncology spaces from larger, better-resourced companies.

Competitive Landscape

Competes with other biotechs developing IRAK4 inhibitors (e.g., Kymera) and a crowded field of DLBCL therapies including CAR-T and bispecific antibodies. Its oral immune checkpoint candidates are in a nascent but competitive field. As a small-cap company, its main challenge is executing clinical trials efficiently to compete for partnership and investment.